Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Argus Health
Johnson and Johnson
Farmers Insurance
Moodys
Cantor Fitzgerald
AstraZeneca
Cerilliant
Queensland Health

Generated: July 19, 2018

DrugPatentWatch Database Preview

NEVANAC Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Nevanac, and what generic alternatives are available?

Nevanac is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are three patents protecting this drug.

This drug has twenty-six patent family members in twenty-two countries.

The generic ingredient in NEVANAC is nepafenac. There are eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the nepafenac profile page.
Drug patent expirations by year for NEVANAC
Generic Entry Opportunity Date for NEVANAC
Generic Entry Date for NEVANAC*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage::
SUSPENSION/DROPS;OPHTHALMIC

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NEVANAC
Synonyms for NEVANAC
0J9L7J6V8C
2-(2-Amino-3-benzoyl-phenyl)-acetamide
2-(2-amino-3-benzoyl-phenyl)acetamide
2-(2-Amino-3-benzoylphenyl)acetamide
2-[2-amino-3-(benzoyl)phenyl]acetamide
2-[2-amino-3-(phenylcarbonyl)phenyl]acetamide
2-amino-3-benzoyl-benzeneacetamide
2-Amino-3-benzoyl-phenylacetamide
2-Amino-3-benzoylbenzeneacetamide
281N728
78281-72-8
A26218
AB0031799
AB01274763_02
AB01274763-01
AB1008448
AC-6949
AC1L45MC
AC1Q4ZKX
ACT02914
AHR 9434
AHR-9434
AK323236
AKOS005146108
AL 6515
AL-6515
Amfenac amide
AN-606
API0003541
AS-19176
BC677673
Benzeneacetamide, 2-amino-3-benzoyl-
CAS-78281-72-8
CHEBI:75922
CHEMBL1021
CN0055
CS-0899
D02IHW
D05143
DB06802
DR000704
DSSTox_CID_28564
DSSTox_GSID_48638
DSSTox_RID_82836
DTXSID0048638
EX-A1350
FT-0080494
FT-0603701
GTPL7564
HMS3654P07
HY-17357
I14-1056
J-507774
KB-58126
KS-000011BS
LS-186492
LS-187354
MFCD08067732
MLS003915618
MLS004774140
MLS006010644
MolPort-003-987-236
N0932
NCGC00185741-01
NCGC00185741-02
Nepafena
Nepafenac
Nepafenac (JAN/USAN/INN)
Nepafenac [USAN]
Nepafenac, >=98% (HPLC)
nepafenaco
nepafenacum
Nevanac (TN)
OR341072
PubChem17348
QEFAQIPZVLVERP-UHFFFAOYSA-N
RL05033
s1255
SBB067082
SC-20092
SCHEMBL93835
SMR002529588
SR-01000931908
SR-01000931908-2
STL451069
TL8005351
Tox21_112985
Tox21_112985_1
UNII-0J9L7J6V8C
W-5364
X5012
ZINC5162311

US Patents and Regulatory Information for NEVANAC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp NEVANAC nepafenac SUSPENSION/DROPS;OPHTHALMIC 021862-001 Aug 19, 2005 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Novartis Pharms Corp NEVANAC nepafenac SUSPENSION/DROPS;OPHTHALMIC 021862-001 Aug 19, 2005 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Novartis Pharms Corp NEVANAC nepafenac SUSPENSION/DROPS;OPHTHALMIC 021862-001 Aug 19, 2005 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for NEVANAC

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0716600/01 Switzerland ➤ Sign Up PRODUCT NAME: NEPAFENAC; REGISTRATION NUMBER/DATE: SWISSMEDIC 58745 24.09.2008
301 Luxembourg ➤ Sign Up PRODUCT NAME: NEPAFENAC-SUSPENSION OPHTALMIQUE
2013 00055 Denmark ➤ Sign Up PRODUCT NAME: NEPAFENAC (3 MG/ML), HERUNDER NEPAFENAC I KOMBINATION MED GLACTOMANNANPOLYMERER, ISAER 3 MG/ML NEPAFENAC I KOMBINATION MED GALACTOMANNANPOLYMERER, SAMT OFTALMISKE SAMMENSAETNINGER DERAF; REG. NO/DATE: EU1/07/433/002 20130503
2013000085 Germany ➤ Sign Up PRODUCT NAME: NEPAFENAC (OPHTHALMISCHE SUSPENSION); REGISTRATION NO/DATE: EU 1/07/433/002 20130503
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Accenture
Fuji
Fish and Richardson
Citi
Cerilliant
Chubb
Argus Health
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.